ArticleBMC geriatrics2025
Serum uric acid and the risk of major adverse cardiovascular events and death among older adults: a population-based prospective cohort study.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between serum uric acid (SUA) and adverse outcomes in advanced age remains poorly understood. Our population-based prospective cohort study assessed the potential association between SUA levels and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among community-dwelling older adults.
methodsWe used data from the Berlin Initiative Study linked to administrative claims and vital statistics. Cohort members were followed from cohort entry (2009) until the occurrence of a study outcome or the end of the study period (2021). We created three exposure groups according to the baseline SUA distribution (in mg/dL; lower: 1.68–5.16, intermediate: 5.17–6.83, higher: 6.84-13.0); SUA levels were updated biennially. Time-dependent Cox models yielded hazard ratios (HRs) and 95% confidence intervals (CIs) of MACE and all-cause mortality adjusted for potential confounders. Sensitivity analyses addressed time-dependent confounding.
resultsOur cohort included 2,058 individuals (mean age 80 years, 53% female). Lower vs. intermediate SUA levels were not associated with the risk of MACE (HR, 1.16; 95% CI, 0.88–1.54) or all-cause mortality (HR, 1.06; 95% CI, 0.86–1.31). Higher vs. intermediate SUA levels were not associated with the risk of MACE (HR, 1.11; 95% CI, 0.85–1.45) but with an increased risk of all-cause mortality (HR, 1.26; 95% CI, 1.03–1.53). Sensitivity analyses showed no statistically significant associations between higher vs. intermediate SUA levels and the risk of mortality (HR [95% CI]: 1.09 [0.89–1.34] & 1.07 [0.86–1.34]).
conclusionLower or higher SUA levels are not associated with the risk of MACE or all-cause mortality in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.